Renting Rubin : AstraZeneca II – Patients First, Provided The State Pays More

AstraZeneca controversies examined in Renting Rubin through Daniel Rubin’s secondment and the company’s regulatory record

AstraZeneca drug pricing is where the company’s patient-first poetry meets somebody holding a calculator.

The poetry does not survive.

Part One opened AstraZeneca’s regulatory history. Seroquel, Zoladex, Dan Markingson, improper-payment findings, product-liability settlements, disputed trial data and a live Chinese prosecution all came out carrying paperwork.

We are not reheating any of it.

Part Two follows the invoice.

It follows Farxiga from a $556 monthly list price to a $178.50 Medicare deal. Then comes AstraZeneca in federal court, arguing that drug-price negotiation interfered with constitutionally protected property interests. Safety-net clinics enter next, alleging a price-fixing conspiracy over statutory discounts. The trail continues through patents challenged by the Federal Trade Commission, an inhaler cap with an industrial-sized asterisk and British investment that froze when government terms disappointed, then thawed after the NHS agreed to pay more.

AstraZeneca says it puts patients first.

The public record suggests patients may enter after the patents, the price, the rebate, the tariff arrangement and whichever government has arrived carrying the larger chequebook.

Welcome back to Renting Rubin.

Daniel Rubin And The Second Dose

Horsfield Menzies advertises Daniel Rubin as an employment lawyer experienced in strategic change, restructurings, redundancies, outsourcing and sensitive investigations. His profile says reputation management and investor confidence are key to those projects.

It also says he spent time on secondment to AstraZeneca.

That is why the company entered this series. Its own record is why it has earned a sequel.

We do not know whether Rubin was involved in any of the events below, advising on something else, or eating somewhere. His biography does not say.

It does place AstraZeneca in his professional shop window. TCAP has returned to examine the pricing label.

The first article dealt with conduct inside the laboratory, the sales operation and the compliance archive. This one deals with a more elemental corporate appetite: the belief that public health systems should remain grateful, governments should remain generous and nobody should ask too loudly why the published price can lose most of its bodyweight the moment a serious negotiator enters the room.

AstraZeneca Patients First – In Corporate Calligraphy

AstraZeneca’s values are admirably concise.

It follows the science. It puts patients first. Playing to win comes next. Doing the right thing makes the list. Entrepreneurship completes it.

Those phrases share one webpage without apparently fighting.

The tension begins when “patients first” meets “play to win”. One is a moral promise. The other is a commercial instruction. When both cannot occupy the same chair, the annual report provides a useful clue about which one receives the armrests.

This is not an argument that medicines should be free or research should be financed with raffle tickets. Drug development is expensive, failure is common and AstraZeneca invested $14.2 billion in science during 2025. Its medicines treat serious disease. Profit does not invalidate science, and science does not abolish the cost of producing it.

However, none of that turns a price into holy scripture.

Nor does it create a constitutional right to have a public health programme swallow whatever number emerges from the mouth of a multinational.

AstraZeneca tested that proposition anyway.

Farxiga And The 68% Price Cut

Farxiga is used to treat diabetes, heart failure and chronic kidney disease. It is not a lifestyle trinket or a tablet for people with too much spare cash. For many patients, it is serious medicine for serious illness.

Farxiga generated more than $4.34 billion in Medicare Part D gross covered prescription costs during 2023. About 994,000 enrollees used it.

The published list price for a 30-day supply was $556.

Under the first round of the Medicare Drug Price Negotiation Program, the agreed price for 2026 became $178.50.

That is a 68% reduction from the 2023 list price.

List price is not the same as AstraZeneca’s previous net receipt. Rebates, discounts and other concessions mean the company was not necessarily banking $556 every time a patient left a pharmacy. The CMS comparison does not prove a 68% profit margin, and TCAP will not pretend that it does.

It proves something simpler.

The public number had enough air inside it to fall by more than two thirds when the United States government was finally permitted to negotiate.

The medicine remained available. AstraZeneca remained solvent. The laboratory lights stayed on. Pascal Soriot did not have to take in ironing.

CMS and AstraZeneca exchanged offers, held negotiation meetings and reached an agreed maximum fair price. Yet while that process continued, AstraZeneca was also trying to dismantle the machinery that made it possible.

Patients first had encountered a counteroffer.

AstraZeneca Discovers The Constitution In A Pharmacy Queue

AstraZeneca sued the US health authorities in August 2023.

Its case challenged the Medicare negotiation programme and parts of the guidance used to administer it. The company argued, among other things, that the programme deprived it of protected property interests without adequate due process.

The asserted property included its patented drugs and the revenue it believed those rights allowed it to determine.

That is magnificent corporate theology.

Develop a medicine. Obtain a patent. Sell into a public programme. Then treat the desired revenue as a property interest with the constitutional status of a family home being seized at dawn.

The Third Circuit Court of Appeals was not persuaded.

In May 2025, it affirmed judgment for the government. Patent law gives an inventor exclusionary rights, the court explained, but it does not create an affirmative right to sell anything. Consequently, it does not create a right to sell at a particular price.

The court went further. AstraZeneca had no protected property interest in selling to Medicare beneficiaries at a price above what the government was willing to reimburse.

Translated from appellate English: owning the medicine does not mean owning the public purse.

AstraZeneca took the matter to the US Supreme Court. On 18 May 2026, the justices declined to hear the appeal.

That denial was not a fresh judgment endorsing every line below. It left the Third Circuit ruling standing and ended AstraZeneca’s route through that case.

The constitutional ambulance had reached the highest court in the country.

Nobody opened the doors.

The Injury AstraZeneca Could Not Show

The appellate opinion contains another revealing failure.

AstraZeneca said the government’s guidance could distort decisions about research, development and marketing. It submitted evidence from its vice-president of US market access about diminished incentives and possible future effects.

The court found the evidence too conjectural.

AstraZeneca had not identified a concrete development or marketing decision it had actually made because of the challenged guidance. It had described risks, possibilities and unspecified pathways. The company spoke of injury with the grave expression of a man approaching triage, then failed to point to the wound.

That does not mean pricing policy can never affect pharmaceutical investment. Of course it can. Commercial incentives matter.

It means this particular company arrived in this particular case alleging constitutional damage and could not produce sufficient evidence of a concrete injury from the guidance it attacked.

Meanwhile, the injury experienced by a patient paying towards an inflated prescription requires no affidavit from the vice-president of anything. It appears every month at the pharmacy.

Safety-Net Clinics And A Plausible Price-Fixing Conspiracy

Farxiga is not AstraZeneca’s only live American pricing problem.

Mosaic Health and Central Virginia Health Services operate safety-net clinics serving low-income and underserved communities. Together, they brought a proposed class action against AstraZeneca, Sanofi, Eli Lilly and Novo Nordisk.

The clinics allege that the four manufacturers conspired to restrict statutory discounts on diabetes medicines supplied through contract pharmacies.

The discounts arise under the federal 340B programme. Manufacturers participating in Medicaid must offer covered outpatient medicines to qualifying providers at or below a statutory ceiling price. Because many safety-net providers lack their own pharmacy, the programme has long operated through arrangements with community pharmacies.

According to the proposed complaint, the manufacturers had provided discounts through those pharmacies for years. Then, during 2020, restrictions arrived in close formation.

AstraZeneca informed the US Department of Health and Human Services that, from October 2020, it would generally stop offering 340B discounts through contract pharmacies. Its exception allowed a provider without an in-house pharmacy to select one contract pharmacy.

Other manufacturers announced their own restrictions around the same period. The clinics alleged parallel conduct, shared lobbying connections and other facts supporting an agreement among competitors.

Initially, the trial court dismissed the case. In 2025, the Second Circuit reversed that outcome.

Its amended opinion held that the proposed complaint contained enough factual material to support a plausible inference of a horizontal price-fixing conspiracy. The court vacated the dismissal and sent the case back so the clinics could file that complaint and proceed.

Plausible Is Not Proven

This is a pleading decision, not a verdict.

The appellate court was required at this stage to accept well-pleaded facts as true and draw reasonable inferences for the clinics. No jury has found that AstraZeneca joined a conspiracy. Discovery may support the allegations, weaken them or kill them.

However, “unproven” is not the same as “invented”. A federal appellate court examined the proposed case and held that the alleged conspiracy was plausible enough to enter litigation rather than die in reception.

AstraZeneca and the other manufacturers have now asked the Supreme Court to reverse that ruling. As of 11 August 2026, AstraZeneca’s petition has been distributed for the justices’ conference on 28 September.

The case is live.

So is the obscenity at its centre: clinics serving poor patients say some of the world’s largest drug companies moved together to narrow a discount programme, and the companies’ present priority is preventing the allegation from reaching the evidential stage.

Patients first.

Discovery, if absolutely fucking necessary.

Patients First, Provided The Pharmacy Is The Right Shape

The 340B dispute exposes how corporate benevolence behaves when it meets infrastructure that the corporation does not control.

A safety-net clinic without an in-house pharmacy still has patients. Those patients still need diabetes medicine. The contract pharmacy is not a decorative middleman. It is how a provider with limited facilities places the medicine into somebody’s hand.

AstraZeneca’s restriction did not abolish every contract-pharmacy arrangement. The company allowed one for providers without their own dispensing pharmacy. That detail matters.

So does the bottleneck.

One pharmacy can be a long drive, the wrong opening hours or an unusable option for a patient juggling illness, work, disability and poverty. “Access” survives beautifully on the spreadsheet while failing several bus routes away.

The clinics allege that the restrictions caused them substantial financial loss. Those savings helped organisations that provide sliding-fee care to people who do not enter a consultation carrying a platinum insurance card and a personal banker.

AstraZeneca’s values say it recognises patients as people first.

Its litigation position currently asks whether those people’s clinics have pleaded with enough technical precision to investigate what happened to the discount.

The patient remains first in the slogan.

The manufacturer controls the queue.

The Orange Book With Pages Stuck Together

Patents reward invention. They can also become architecture around a market, each new filing another locked door between a cheaper competitor and the prescription counter.

The US Food and Drug Administration publishes approved drug patents in the Orange Book. Certain listings can help trigger an automatic 30-month stay of approval for a generic challenger if the brand manufacturer brings patent litigation.

Accuracy therefore matters.

In November 2023, the Federal Trade Commission told AstraZeneca that it believed ten Symbicort patent listings were improper or inaccurate. The agency used the FDA’s regulatory process to dispute them.

Five months later, the FTC challenged eight patent listings for AstraZeneca’s Bydureon Pen on the same basis.

The FTC warned that improper listings can delay cheaper generic competition, increase costs and discourage investment by generic manufacturers forced to litigate patents that should not be sitting in the Orange Book.

These letters are regulatory challenges, not final court findings that AstraZeneca violated antitrust law. The company was entitled to respond through the FDA process. TCAP does not need to inflate the record because the record already arrived with eighteen disputed listings and a federal regulator carrying a crowbar.

A valid patent protects an invention.

An improper listing can protect a revenue stream while a cheaper medicine waits outside for thirty months.

That is why “patients first” cannot be assessed through discovery science alone. It must also be examined in the less photogenic offices where exclusivity is extended, challenged, certified and billed by the hour.

The white coat develops the medicine.

The Orange Book decides how long the moat stays full.

Forxiga And The Patent That Failed Its Own Clinical Endpoint

AstraZeneca’s patent position also received treatment in Britain.

Forxiga is the UK name for the same medicine sold as Farxiga in America. In April 2025, the UK Patents Court held the relevant Forxiga patent invalid.

AstraZeneca appealed and sought to keep generic competitors off the market while it pursued the case. The Court of Appeal rejected the substantive application for a longer injunction after concluding that the proposed appeal had no real prospect of success. The UK Supreme Court then refused permission to appeal.

Generic dapagliflozin products entered the British market in August 2025.

AstraZeneca itself disclosed that sequence to investors in its March 2026 aide-mémoire. It also told them that the UK ruling did not directly affect Forxiga patents elsewhere.

Fair enough.

Patents are territorial, and one failed UK case does not dissolve rights across the planet. Yet the chronology belongs beside the American price litigation.

In Britain, AstraZeneca tried to keep generics outside after its patent was held invalid.

In America, it tried to stop the government negotiating the price of the branded product.

Different laws. Different proceedings. Same commercial reflex: defend the perimeter until the final court removes the last sandbag.

Thirty-Five Dollars And One Industrial Asterisk

AstraZeneca announced that eligible American patients would pay no more than $35 per month for its inhaled respiratory medicines from June 2024.

That cap can make a real difference. A patient who can breathe because a medicine became affordable is not a public-relations abstraction, and TCAP is not going to sneer at the saving.

Then comes the asterisk.

AstraZeneca’s own affordability page says government restrictions exclude people enrolled in federal government insurance programmes from co-pay support. Those who do not meet the terms may be eligible for a separate AZ&Me assistance programme.

That is a more complete picture than the headline.

Eligible patients receive the cap. Some patients on federal insurance cannot use the co-pay offer. Another programme may help some of them. The word “eligible” carries the whole administrative wardrobe on one exhausted syllable.

The small print is not buried quite as deeply as a favourable search result for Sam Butler, but it decides who reaches the advertised number.

There is also an awkward chronology.

AstraZeneca announced the cap months after the FTC challenged its Symbicort patent listings. The FTC later noted the company’s commitment while announcing its wider campaign against what the agency called junk patent listings.

The patent moat attracted a federal challenge.

Affordability then arrived at $35 carrying an asterisk and a press release.

Perhaps the two events were entirely independent. Perhaps corporate compassion simply checked its diary at an unusually convenient moment.

Either way, the patient had been first for years. It merely took regulatory attention to improve their place in the fucking queue.

Speke And The £450 Million Lever

AstraZeneca’s pricing power does not end at the pharmacy. It also appears in decisions about where factories, laboratories and jobs will live.

In March 2024, the company announced a planned £650 million British investment package. It included £450 million for expansion of the vaccine manufacturing facility at Speke and £200 million for Cambridge.

The Speke proposal came with an expected public contribution.

The previous government had indicated support worth about £90 million, subject to due diligence. After the change of government, the final offer fell. AstraZeneca cancelled the investment in January 2025, citing the timing and reduction of government support.

That was the company’s account.

Parliament then heard the government’s less flattering version. AstraZeneca had changed the composition of the proposal and reduced the UK research-and-development element from £150 million to about £90 million. Ministers said public support therefore had to change as well.

The argument became a national plate fight.

AstraZeneca said the state had weakened its offer. The state said AstraZeneca had weakened the project. Merseyside was left with the existing facility and none of the promised expansion while two wealthy institutions blamed each other over who had moved which pile of money first.

No existing Speke jobs were lost through that decision, according to the government. The proposed new investment, additional capability and associated opportunity were lost.

This is what corporate leverage looks like without the investor-relations lighting.

A project is announced beside ministers. Jobs and national resilience are placed on the table. Public support becomes part of the arithmetic. When the arithmetic disappoints, the ribbon-cutting scissors go back into their velvet case and an entire region becomes a sentence about commercial discipline.

AstraZeneca reported $58.7 billion in revenue for 2025.

It still required the taxpayer’s offer to achieve the correct fucking molecular structure.

Britain Pays More And Cambridge Wakes Up

The remaining £200 million Cambridge project was paused in September 2025. By then, AstraZeneca and the wider pharmaceutical industry were openly dissatisfied with British medicine pricing, reimbursement and access decisions.

Then the state moved.

The formal UK-US pharmaceutical arrangement published in April 2026 committed Britain to increase the net price paid by the NHS for prospective new medicines by 25%. It raised the usual NICE cost-effectiveness threshold from £20,000–£30,000 per quality-adjusted life year to £25,000–£35,000.

The agreement also capped the main industry repayment rate under the voluntary pricing scheme at 15% for 2026 and promised that it would remain at or below that level while the scheme continued. Britain further committed to doubling spending on new medicines as a share of GDP by 2036.

Cambridge Comes Back From The Dead

Twenty-seven days after the arrangement was published, Keir Starmer announced £300 million of AstraZeneca investment in Cambridge and Macclesfield.

The Prime Minister told Parliament that the investment had been made possible by the pharmaceutical arrangement with the United States.

The Cambridge project came back from the dead. AstraZeneca would complete the £200 million Rosalind Franklin building. A further £100 million would fund a digital and data-led laboratory in Macclesfield.

Pascal Soriot thanked the government for improving patient access. In July, he specifically praised the first increase in the NICE threshold since 1999.

Of course he did.

When Medicare sought to pay less, AstraZeneca found the Constitution.

When Britain agreed to pay more, AstraZeneca rediscovered Cambridge.

The company will say these changes improve access and reward innovation. The government will say better commercial terms attract investment and bring treatments to NHS patients. Both claims can contain truth.

The timing still has all the subtlety of a suitcase changing hands beneath a restaurant table.

Investment paused amid a pricing dispute. Government promised higher net prices and lower clawbacks. Investment resumed before the ink had time to become emotionally available.

Speke’s £450 million expansion remains cancelled.

Cambridge and Macclesfield got the comeback tour. Merseyside kept the old poster.

The Price Becomes Flexible When A President Arrives

AstraZeneca’s American deal adds another layer of corporate elasticity.

In October 2025, the company announced what it called a historic agreement with the Trump administration. Eligible patients with prescriptions for chronic diseases would receive direct-to-consumer discounts of up to 80% from list prices through a federal purchasing platform.

At the same time, AstraZeneca reached an arrangement to delay possible Section 232 pharmaceutical tariffs for three years while it moved towards manufacturing all medicines sold in America inside the country.

The company linked this to a planned $50 billion investment in US manufacturing and research by 2030. Its specific pricing terms remained confidential.

There is nothing wrong with patients paying less. There is nothing inherently sinister about domestic manufacturing. The revelation lies in how quickly price becomes negotiable when the customer arrives with sovereign power, tariff authority and a television crew.

An individual patient sees a list price.

Medicare brings legislation and obtains 68% off Farxiga’s old list price.

The White House brings tariffs and announces discounts of up to 80% for eligible direct purchasers.

Britain brings a 25% net-price increase and receives £300 million of revived investment.

The molecule does not change between these rooms.

The leverage does.

AstraZeneca’s public language treats each outcome as a fresh expression of patient access. In reality, the price behaves like a nightclub doorman: rigid with the sick, charming with power and suddenly able to find space when somebody important arrives.

Pascal Soriot And The Affordable Executive

Pascal Soriot received £17.7 million in pay, bonus and long-term share awards for 2025.

That included about £1.5 million in salary, £4.3 million in annual bonus and £11.6 million from long-term incentives. AstraZeneca’s reporting placed his realised pay at roughly 176 times that of the average employee.

The company had a strong year. Revenue reached $58.7 billion. Its share price rose, its pipeline advanced and shareholders received value. Soriot did not steal his remuneration from a collection tin outside respiratory clinic B.

However, executive pay is where a company’s abstract language about scarcity becomes touchingly specific.

There is always money for performance. Revised incentive policies always find headroom. A consultant is always available to explain why global competition requires another sack of shares to be lowered through the roof.

Then a public health system seeks a lower medicine price and innovation itself is found tied to the railway tracks.

AstraZeneca says reducing revenue may weaken research incentives. Asked for concrete injury, it offers conjecture. Meanwhile, the chief executive’s package arrives down to the final hundred thousand without comparable fog.

This is not a demand that Soriot work for minimum wage.

It is a demand that nobody genuflect when a company paying one man £17.7 million describes negotiation by a healthcare programme as deprivation.

AstraZeneca wants $80 billion in annual revenue by 2030.

Patients first is a value.

Revenue gets a number.

The Reputation Management Price List

Horsfield Menzies says reputation management and investor confidence are key to Daniel Rubin’s work. AstraZeneca remains a remarkable name to display beside that claim.

Part One showed why reputation management might be needed.

Part Two shows what it is often protecting.

The company fought Medicare negotiation through the federal courts while agreeing to a Farxiga price 68% below the old list figure. Safety-net clinics have pleaded a plausible antitrust conspiracy over statutory discounts, and AstraZeneca is asking the Supreme Court to stop that case proceeding. The FTC challenged eighteen AstraZeneca patent listings across two products. British investment froze, public pricing terms improved, and £300 million promptly thawed.

No communications strategy can make those events identical, because they are not.

Together, however, they reveal a governing instinct.

Price is defended as innovation.

Patent is defended as science.

Investment is defended as confidence.

Executive reward is defended as competition.

Every route leads back to the company’s entitlement to more money, protected by a bodyguard made of sick people and research jobs.

Question the price and patients may lose innovation.

Challenge the public subsidy and workers may lose investment.

Dispute the patent and generic access may wait.

Probe the statutory discount and the clinic may spend years trying to reach discovery.

It is less a business model than a hostage note typeset by McKinsey.

Patients Somewhere In The Footnotes

AstraZeneca makes valuable medicines. That fact survives every criticism in this article.

It also makes choices about prices, patents, discounts, litigation, investment and pay. Those choices are not science. They are exercises of power conducted around science, with patients repeatedly carried into the room as moral hand luggage.

The company’s own record shows that a price can fall by 68% when Medicare negotiates. It can fall by up to 80% for eligible patients when tariffs and presidential pressure enter the discussion. Meanwhile, Britain agreed to raise the net price for prospective new medicines by 25% while seeking investment.

This is not a fixed relationship between research cost and a morally correct price.

It is bargaining.

Power bargains well. Patients bargain alone.

Daniel Rubin’s biography brought AstraZeneca into Renting Rubin. AstraZeneca’s conduct brought it back.

The company was his credential.

The public record is ours.

At AstraZeneca, the medicine may be life-changing. The price is constitutional, negotiable, confidential or patriotic depending on who is holding the other end of the contract.

That is not patients first.

That is power first, payment second and patients somewhere in the fucking footnotes.

Renting Rubin will keep reading them.

Lee Thompson – Founder, The Cummins Accountability Project